Archive for the ‘Virus Killer’ Category

THE SECRET KILLER Glasgow dentist uses new technology to diagnose symptoms of potentially fatal disease we need to …

Scotland has the highest rate of mouth cancer anywhere the UK, with more than 700 people diagnosed annually.

It has one of the country's fastest-growing rates of all cancers.

In the NHS Greater Glasgow and Clyde area there were 137 cases of oral cavity cancer diagnosed in 2010, compared with 102 cases in 2000 and 74 cases in 1990.

There were 44 deaths from mouth cancer in the NHSGGC area in 2011, compared with 46 deaths from skin cancer.

Mouth cancers kill more people each year than cervical cancer and testicular cancer combined.

Scotland's rates of smoking, alcohol drinking, and poor diet are all risk factors but new technology is being used to spot early signs of the disease.

Glasgow dentist Dr Attiq Rahman is using cutting-edge technology to detect early signs of oral cancer.

He said oral cancer can prove deadly because it can spread before any symptoms are noticeable.

He said: "Secondary lesions or metastases tend to spread rapidly and they can be quite distant from the primary site of the abnormality.

"With other signs of cancer, there are early symptoms that are unmistakable. With mouth cancer, the tissue can look normal for quite some time.

Here is the original post:
THE SECRET KILLER Glasgow dentist uses new technology to diagnose symptoms of potentially fatal disease we need to ...

It’s not just the killer flu epidemic: Triple-threat cocktail of viruses sickening nation

As if the flu wasnt bad enough. Now doctors say two other viruses are piling on making this one of the sickest winter seasons theyve ever seen. And it could get worse before it gets better.

At Winthrop Hospital, doctors say the emergency room is overflowing with patients suffering from a number of symptoms.

Hospitals are filled and when the hospitals are filled, sick patients in the emergency department cant be moved up to beds, said Dr. Barry Rosenthal of Winthrop Department of Emergency Medicine

Rosenthal says two viruses are combining with the flu to form a triple-threat putting every healthy person at risk.

We have the influenza. We have the upper respiratory infection which is caused by a rhino-virus and then theres also a stomach bug out there caused by another virus.

Making matters worse- experts are calling this flu season one of the most aggressive theyve seen in years.

The Center For Disease Control says, the flu is now widespread in 47 states. 20 children have already died from the virus.

In New York alone, there have been more than 15,000 reported cases. Thats already more than three times the total number of flu cases reported last year. sick.

And with the epidemic growing many procrastinators have been rushing to get their flu shot.

So far the government has handed out more than 130-million dosesmaking it difficult to find in certain areas.

Go here to read the rest:
It’s not just the killer flu epidemic: Triple-threat cocktail of viruses sickening nation

GeoVax Announces Enrollment Completion for Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine

ATLANTA, GA--(Marketwire - Jan 10, 2013) - GeoVax Labs, Inc. ( OTCQB : GOVX ), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and treat HIV/AIDS, announced it has completed enrollment in a nine-patient Phase 1/2 clinical trial testing the safety, immunogenicity and ability of its DNA/MVA vaccine to elicit protective immune responses in HIV-infected individuals.

The primary goal of this study is to document the safety and immunogenicity of GeoVax's vaccine in HIV-positive patients with well-controlled infections using oral HIV drug medication. Following vaccination, the trial includes a short period of drug-interruption to evaluate the ability of the vaccine to control the infection in the absence of continuing drug therapy. The Phase 1/2 trial (designated GV-TH-01) consists of priming with a recombinant DNA vaccine followed by boosting with a recombinant modified vaccinia Ankara (MVA) vaccine. The vaccine regimen elicits both antiviral antibody that can block infection and antiviral T cells that can recognize and kill infected cells. The trial is being conducted at the AIDS Research Consortium of Atlanta, the Alabama Vaccine Research Center at the University of Alabama, Birmingham and the AIDS Research Alliance of Los Angeles.

Robert McNally, Ph.D., President and CEO of GeoVax, stated, "This pilot study is our first trial investigating use of a therapeutic vaccine to address the need for a treatment that is better tolerated and less costly than the HIV oral medications currently available. We anticipate having meaningful data from the program later this year."

Harriet Robinson, GeoVax's Chief Scientific Officer, commented, "Our next step planned for our therapeutic vaccine development program is a Phase 1 clinical trial to investigate the use of our vaccine in combination with standard-of-care drug therapy in young adults. This trial will likely be conducted by the International Maternal Pediatric Adolescent AIDS Clinical Trial Group (IMPAACT). One of the hopes for therapeutic vaccination is that combining a vaccine with drugs will allow the eradication of virus from an infected individual. Drugs primarily prevent infection whereas a vaccine can both block infection and kill infected cells."

About GeoVax

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV. GeoVax's vaccines are unique in expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from a Phase 1 study supported a Phase 2a trial that was completed in the 3rd quarter of 2012.

GeoVax's 2nd generation preventive vaccine is currently in phase 1 testing and is planned to progress to phase 2 efficacy testing, given safety and immunogenicity are as expected. Overall, the GeoVax vaccine, in various doses and combinations, has been tested in close to 500 humans. GeoVax is also enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV. For more information, please visit http://www.geovax.com.

About HIV/AIDS

HIV infection, which can lead to AIDS, is a pandemic that can affect anyone, regardless of race, gender, age, or sexual orientation. 33 million people are currently infected globally; it is estimated that there will be 2.5 million new infections this year. Since the beginning of the epidemic, more than a million people in the U.S. have contracted the virus. Every 9 1/2 minutes, someone in the U.S. is infected with HIV. Globally, HIV is the top killer among women of reproductive age. HIV is a worldwide disease with different subtypes (or clades) of the virus predominating in different regions of the world. Clade B is the predominant subtype in North America. Globally, most infections involve subtypes AG, B and C. GeoVax vaccines are currently designed to function against clade B.

For more Information, please visit http://www.geovax.com.

Go here to see the original:
GeoVax Announces Enrollment Completion for Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine

5 Things to Know This Morning

Your look at the five biggest and most buzz-worthy stories of the morning.

1. Killer Whales Trapped Under Sea Ice

A community in Quebec is calling for outside help to free about a dozen killer whales that are trapped under a large stretch of sea ice. Locals say the mammals have gathered around a hole in the ice to get oxygen.

2. Flu Prompts Boston Public Health Emergency

An early flu season has prompted a public health emergency in Boston, where 700 people have been diagnosed with the virus. Four Boston residents - all elderly - have died from the flu. At this time last year, the city had only seen 70 cases of influenza.

3. China Snubs U.S. Investor Fraud Request

The Chinese government has snubbed a U.S. request to help crack down a string of alleged investment frauds that have cost Americans billions of dollars, according to Securities and Exchange Commission Chairman Mary Schapiro. The lack of cooperation has stunted efforts to recoup investor losses.

4. Monopoly Tokens to be Eliminated

One of eight iconic Monopoly tokens will soon be eliminated. Hasbro is holding a Facebook contest to determine which one of the tokens that identifies players will be eliminated so they can introduce a new one.

5. Dog Treats Taken Off Market

Visit link:
5 Things to Know This Morning

Killer virus sparks warning Save

Jan. 10, 2013, 11:49 a.m.

A highly contagious virus that is deadly to dogs has appeared in western Queensland, with three animals infected in a week.

Cases of canine parvovirus reappeared at veterinary clinics in Mount Isaover the weekend, sparking calls for residents to take precautionary measure to protect their pets.

Paws, Hoofs and Claws Charity president Sue Carson admitted three dogs with the potentially fatal virus to the veterinary last week.

Bear, a four-month old collie cross and two newborn French-Boxer cross puppies were still recovering from the illness.

Mrs Carson said the highly contagious virus existed anywhere infected animals had been and could lay dormant in the ground for morethan a year.

"It's passed through bodily fluids like urine and faeces," she said.

"Its not just in backyards, it can affect parks and footpaths too."

Mrs Carson said people new to Mount Isa or thinking about purchasing a new pet needed to be wary of where they took their dogs.

"It's a timely warning for the residents of Mount Isa," she said.

Read more from the original source:
Killer virus sparks warning Save